The world has woken up to a new era, with Donald Trump elected as US president – a huge victory for a political outsider and the 'silent majority' who felt sidelined by the status quo.

During election cycles, much is made of policy positions on the economy, immigration, foreign affairs, etc. However, rarely is attention paid to the policy of science. With every vote, Americans ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

Nearly 700,000 women will be recruited into an NHS trial of artificial intelligence (AI) tools for breast cancer screening in an attempt to spot the disease earlier and save lives. The EDITH ...

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance in the final quarter of last year, helping to drive group revenue growth of 30% – but don't expect that breakneck ...

2024 was pivotal for UK Life Sciences’ venture funding landscape. Softening macro and geopolitical conditions saw activity rebound, setting the stage for an upwards trajectory in 2025.

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain, another positive development in the search for alternatives to opioids.

2025 will be a challenging year for many sectors with multiple headwinds, and the pharmaceutical industry is no exception. The industry is grappling with significant market shifts amidst emerging ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

It's been reported that the UK government made an offer of £78 million in funding for AstraZeneca's now-abandoned £450 million vaccine facility in Liverpool, but that was not enough to keep the ...

The future of USAID – the world's largest donor of humanitarian aid, including projects to raise the quality and safety of medicines in low- and middle-income countries – is in doubt.

“AI has arrived,” British Prime Minister Keir Starmer declared in a recent speech. “Our defining opportunity is here - and together, we will harness it”, he added, praising the potential ...